• Conavi Medical posted a net loss of CAD 6.3 million for fiscal Q3 2026, widening from CAD 3.6 million a year earlier.
• Revenue held at CAD 0.1 million; operating expenses climbed to CAD 6.5 million from CAD 4.7 million, on higher R&D.
• R&D spending rose to CAD 4.4 million from CAD 3.2 million; cash fell to CAD 0.9 million at June 30.
• Received FDA 510(k) clearance for its next-generation Novasight Hybrid IVUS-OCT system; targeting initial U.S. hospital release in H2 2026.
• Closed a CAD 10 million public offering on Aug. 12; collected a CAD 1.25 million Ontario milestone payment tied to FDA clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Conavi Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270803PRIMZONEFULLFEED9817070) on August 27, 2026, and is solely responsible for the information contained therein.